Nuwellis Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Nuwellis Inc trades at $1.42 (market cap $542.80K), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.87. The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | SJNK | |
|---|---|---|
Market Cap | $542.80K | — |
Sector | Technology | Sector/Thematic |
52-Week High | $220.50 | $25.63 |
52-Week Low | $1.42 | $24.75 |
Enterprise Value | -$1.27M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.41, down 0.7% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with preliminary Q2 2026 revenue up 14% year-over-year, but remains unprofitable with a net income margin of -217.22%. Recent developments include a reverse stock split, new CEO appointment, and expansion of its Aquadex platform into new pediatric markets. Cash flow from operations is negative, though recent financing activities have provided capital.
The outlook is mixed: growth initiatives and analyst support offer potential, but persistent losses and high cash burn pose significant risks. Investors should weigh the company's expansion against its financial sustainability.
SJNK trades at $24.87, up 0.16% over 24 hours, with a bearish technical signal driven by moving averages. The ETF shows neutral oscillators and has announced upcoming dividend payments. Recent news highlights institutional selling, with Cetera Investment Advisers and Balefire LLC reducing positions in Q2 2026.
The outlook remains cautious due to bearish technicals and institutional outflows. Risks include high-yield bond sensitivity to interest rates and economic conditions. Analyst sentiment is negative, with recent articles advising against holding junk bonds amid potential yield headwinds.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →